期刊文献+

小鼠核因子κB受体活化因子配基活性区的克隆、表达及生物活性分析

Cloning,Expression and Bioactivity Analysis of The Active Domain of The Mouse Receptor Activator of NF-κB Ligand
原文传递
导出
摘要 核因子κB受体活化因子配基是诱导破骨细胞分化、成熟的关键因子,在生物医学研究中应用广泛。本实验以小鼠的骨髓细胞cDNA为模板,采用PCR技术获得小鼠核因子κB受体活化因子配基活性区基因,并将该基因克隆至His标签的融合蛋白表达载体pET28a(+),经鉴定正确的质粒转化至BL21表达菌株中。通过调节诱导目的蛋白表达的培养温度、IPTG浓度及诱导时间,筛选出重组融合蛋白表达的最佳条件。将纯化后的重组蛋白稀释成不同浓度,刺激小鼠破骨前体细胞Raw264.7细胞分化,经抗酒石酸酸性磷酸酶染色后可见破骨细胞的形成,表明该重组蛋白具有较好的生物活性,可替代商品化的鼠源核因子κB受体活化因子配基。 Receptor activator of NF-κB ligand plays a key role in inducing osteoclast differentiation and maturation.It is widely used in biomedical researchs.Mouse's marrow cell cDNA was as a template and receptor activator of NF-κB ligand gene was obtained using the PCR technology in the experiment.Then,the gene was cloned with a His tagged fusion protein expression vector pET28a(+).The plasmid which was correct through digested identification was transformed into BL21 Escherichia.coli strain.In order to select the optimum condition for fusion protein,the target protein was expressed at the different temperatures,the IPTG concentrations and the induction times.The purified recombinant protein was diluted to different concentrations and was used to stimulate Raw264.7 cell differentiation.The obvious osteoclasts were observed through tartrate-resistant acid phosphatase staining,which indicated that the reorganization protein has good biological activity and could substitute the commercialized mouse receptor activator of NF-κB ligand.
出处 《生物物理学报》 CAS CSCD 北大核心 2010年第9期790-798,共9页 Acta Biophysica Sinica
基金 上海市科委研发公共服务平台"细胞信号转导网络研究技术"(06DZ22923) 国家自然科学基金(30800653)~~
关键词 小鼠核因子κB受体活化因子配基 基因克隆 原核表达 破骨细胞分化 Mouse receptor activator of nuclear factor-κB ligand Gene cloning Prokaryotic expression Osteoclast differentiation
  • 相关文献

参考文献14

  • 1Leibbrandt A, Penninger JM. RANK/RANKL: Regulators of immune responses and bone physiology. Ann N Y Acad Sci, 2008, 1143:123-150.
  • 2Mundy GR. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer, 2002, 2(8): 584-593.
  • 3Tanaka S, Nakamura K, Takahasi N , Suda T. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev, 2005, 208:30-49.
  • 4Nakashima T, Wada T, Penninger JM. RANKL and RANK as novel therapeutic targets for arthritis. Curr Opin Rheumatol, 2003, 15(3): 280-287.
  • 5Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet, 2003, 4(8): 638-649.
  • 6Takayanagi H. Osteoimmunology: Shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol, 2007, 7(4): 292-304.
  • 7Tanaka S. Nakamura I, Inoue J, Oda H, Nakamura K. Signal transduction pathways regulating osteoclast differentiation and function. J Bone Miner Metab, 2003, 21(3): 123-133.
  • 8Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos A J, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle W J, Penninger JM. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature, 1999, 397(6717): 315-323.
  • 9Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med, 2006, 12(1): 17-25.
  • 10Huang GC, Chien TY, Chen LG, Wang CC. Antitumor effects of zerumbone from Zingiber zerumbet in P-388D1 cells in vitro and in vivo. Planta Med, 2005, 71(3): 219-224.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部